These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 8043545)

  • 21. A case of postmenopausal endometriosis unrelated to neoplasm.
    Kurioka H; Takahashi K; Okada M; Ozaki T; Miyazaki K; Maruyama R; Yoshida M
    Int J Fertil Womens Med; 1999; 44(3):160-2. PubMed ID: 10435916
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Endometrial cancer and hormone-replacement therapy.
    Wiegratz I; Kuhl H
    Lancet; 2005 Jul 16-22; 366(9481):201-2. PubMed ID: 16023504
    [No Abstract]   [Full Text] [Related]  

  • 23. Serum CA-125 levels in women with endometriosis.
    Grover S; Koh H
    Aust N Z J Obstet Gynaecol; 1990 Aug; 30(3):279-80. PubMed ID: 2256870
    [No Abstract]   [Full Text] [Related]  

  • 24. Complex endometrial hyperplasia in the context of tibolone administration.
    Kane SC; Quinn MA
    Aust N Z J Obstet Gynaecol; 2009 Jun; 49(3):338-9. PubMed ID: 19566575
    [No Abstract]   [Full Text] [Related]  

  • 25. [Relation between hormonal therapy and tibolone with SERMs in postmenopausal women's myomes growth].
    Carranza Lira S
    Ginecol Obstet Mex; 2008 Oct; 76(10):610-4. PubMed ID: 19062511
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of ovarian and uterine cancers with postmenopausal hormonal treatments.
    Neves-E-Castro M
    Clin Obstet Gynecol; 2008 Sep; 51(3):607-17. PubMed ID: 18677154
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Tibolone therapy in postmenopausal women with a history of many risk factors].
    Szántó F
    Orv Hetil; 2003 Apr; 144(15):701-4. PubMed ID: 12774429
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized, open-label study of conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone: effects on symptom control, bleeding pattern, lipid profile and tolerability.
    Baracat EC; Barbosa IC; Giordano MG; Haidar MA; Marinho RM; Menegocci JC; Morais KM; Tomaz G; Wehba S
    Climacteric; 2002 Mar; 5(1):60-9. PubMed ID: 11974560
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of hormone replacement therapies and selective estrogen receptor modulators in postmenopausal women with uterine leiomyomas: a literature review.
    Ang WC; Farrell E; Vollenhoven B
    Climacteric; 2001 Dec; 4(4):284-92. PubMed ID: 11770184
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tibolone, blood pressure and obesity.
    Roshan J; Ganesh A
    Natl Med J India; 2002; 15(3):180. PubMed ID: 12186341
    [No Abstract]   [Full Text] [Related]  

  • 31. Tibolone in older postmenopausal women.
    Chlebowski RT; Prentice R
    N Engl J Med; 2008 Nov; 359(20):2172-3; author reply 2173. PubMed ID: 19005202
    [No Abstract]   [Full Text] [Related]  

  • 32. Serum CA 125 levels in patients with endometriosis: changes in CA 125 levels during menstruation.
    Masahashi T; Matsuzawa K; Ohsawa M; Narita O; Asai T; Ishihara M
    Obstet Gynecol; 1988 Sep; 72(3 Pt 1):328-31. PubMed ID: 3165507
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of conjugated estrogen plus medroxyprogesterone acetate versus tibolone in early postmenopausal Chinese women.
    Yang TS; Tsan SH; Chen CR; Chang SP; Yuan CC
    Zhonghua Yi Xue Za Zhi (Taipei); 1999 May; 62(5):308-15. PubMed ID: 10389286
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Postmenopausal metabolic effects of a synthetic estrogen (tibolone) with a characteristic estrogenic action].
    Hernández-Valencia M; Fonseca E; Ochoa R; Zárate A
    Ginecol Obstet Mex; 1997 Apr; 65():145-7. PubMed ID: 9280740
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum CA 125 as a marker for patients with external endometriosis.
    Takahashi K; Kijima S; Yoshino K; Shibukawa T; Kitao M
    Int J Fertil; 1989; 34(2):143-8. PubMed ID: 2565317
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiple serum marker assay in the diagnosis of endometriosis.
    Muscatello R; Cucinelli F; Fulghesu A; Lanzone A; Caruso A; Mancuso S
    Gynecol Endocrinol; 1992 Dec; 6(4):265-9. PubMed ID: 1492582
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnostic value of pelvic examination, ultrasound, and serum CA 125 in postmenopausal women with a pelvic mass. An international multicenter study.
    Schutter EM; Kenemans P; Sohn C; Kristen P; Crombach G; Westermann R; Môbus V; Kaufmann M; Caffier H; Schmidt-Rhode P
    Cancer; 1994 Aug; 74(4):1398-406. PubMed ID: 8055463
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Endometrial effects of tibolone in elderly, osteoporotic women.
    Ettinger B; Kenemans P; Johnson SR; Mol-Arts M; Van Os S; Seifert W; Verweij PJ; Cummings SR
    Obstet Gynecol; 2008 Sep; 112(3):653-9. PubMed ID: 18757665
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of hormone replacement therapy type and route of administration on plasma matrix metalloproteinases and their tissue inhibitors in postmenopausal women.
    Lewandowski KC; Komorowski J; Mikhalidis DP; Bienkiewicz M; Tan BK; O'Callaghan CJ; Lewinski A; Prelevic G; Randeva HS
    J Clin Endocrinol Metab; 2006 Aug; 91(8):3123-30. PubMed ID: 16705077
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tibolone as an alternative to estrogen for the prevention of postmenopausal osteoporosis in selected postmenopausal women.
    Riggs BL
    J Clin Endocrinol Metab; 1996 Jul; 81(7):2417-8. PubMed ID: 8675553
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.